ReviewThe Journal of clinical investigation2025
Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches.
Review in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Phenotypic heterogeneity and genetic mechanisms of phage resistance in hypervirulent carbapenem-resistantVirulence · 2026Article
- Oral virome in health and disease.Journal of the American Dental Association (1939) · 2026Review
- Phage Genomics and Bioinformatics in Therapeutic Development: Evidence Limits, Validation Gates, and Translational Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- NIR-Assisted Multimodal Strategies for Enhanced Antibacterial Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- AI-assisted phage formulation delivered via injectable hydrogels for localized control of implant-associated infections.Bioactive materials · 2026Article
- Inhaled formulations for bacterial pneumonia: Strategies and advances in drug delivery.Bioactive materials · 2026Review
- A Lytic Bacteriophage Cocktail Attenuates Carbapenem-Resistant Klebsiella pneumoniae-Acinetobacter baumannii Mixed-Species Biofilms and Reshapes Transcriptional Responses.Microbial biotechnology · 2026Article
- Pharmacology of Bacteriophage Therapy in Children: A Re-Emerging Paradigm in Antibacterial Therapy.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Antimicrobial Resistance as a Global Public Health Challenge: Epidemiological Burden, Bioethical Dimensions and Emerging Therapeutic Strategies.Infectious disease reports · 2026Review
- From screening to treatment:Microbiology spectrum · 2026Article
- PhageMind: generalized strain-level phage host range prediction via meta-learning.Bioinformatics (Oxford, England) · 2026Article
- Regulating the Irregular: Phage Therapy and the Case for a Regulatory Sandbox Approach in Australia.Pharmaceutical medicine · 2026Article
- Chemical inhibition of a CBASS anti-bacteriophage defense.iScience · 2026Article
- Bacteriophage therapy for multidrug-resistant bacterial infections: recent advances, clinical evidence, and translational challenges.Archives of microbiology · 2026Review
- Characterization of novel phage Henuyfy11N: a potential therapeutic agent against extended-spectrum β-lactamase (ESBL)-producingMicrobiology spectrum · 2026Article
- Article
- Paleopathology Meets Public Health: Deep-Time Syndemics and the Ecology of Emerging Infections.Pathogens (Basel, Switzerland) · 2026Review
- Isolation and characterization of novel bacteriophage, vB_AbaA_SWMUZ8, targeting multidrug-resistant Acinetobacter baumannii strains.BMC microbiology · 2026Article
- Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration-A Review.Infectious diseases and therapy · 2026Review
- Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies.Diagnostics (Basel, Switzerland) · 2026Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Bacteriophage (phage) therapy has emerged as a promising solution to combat the growing crisis of multidrug-resistant (MDR) infections. There are several international centers actively engaged in implementation of phage therapy, and recent case series have reported encouraging success rates in patients receiving personalized, compassionate phage therapy for difficult-to-treat infections. Nonetheless, substantial hurdles remain in the way of more widespread adoption and more consistent success. This Review offers a comprehensive overview of current phage therapy technologies and therapeutic approaches. We first delineate the common steps in phage therapy development, from phage bank establishment to clinical administration, and examine the spectrum of therapeutic approaches, from personalized to fixed phage cocktails. Using the framework of a conventional drug development pipeline, we then identify critical knowledge gaps in areas such as cocktail design, formulation, pharmacology, and clinical trial design. We conclude that, while phage therapy holds promise, a structured drug development pipeline and sustained government support are crucial for widespread adoption of phage therapy for MDR infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.